This company focuses on the development of new drugs, particularly in the areas of immunity, metabolism, and neurological disorders. Their pipeline includes drugs like KBL-697 and KBL-693, which are in Phase 2 and Phase 1 clinical trials respectively.
Contact Details | 700 Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea Biopark Building C, 7th floorTEL : 031-628-2500E-MAIL : info@kobiolabs.com |
---|